News

FDA Approves Novel Dosing Regimen for Cetuximab in CRC, Head and Neck Cancer

04/08/2021

The FDA has approved a higher dose of cetuximab for the treatmen of patients with KRAS wild-type, EGFR-expressing metastatic colorectal cancer or squamous cell carcinoma of the head and neck.

The FDA has approved a higher...

04/08/2021

Oncology

News

Coffee May Reduce Risk for Disease Progression, Death in Patients With CRC

11/12/2020

Findings from a cohort study of patients with advanced or metastatic CRC showed that increased coffee consumption was linked to a lower risk for disease progression and death.

Findings from a cohort study of...

11/12/2020

Oncology

News

High Immunoscore Linked to Prolonged Survival in Stage III Colon Cancer

10/06/2020

An international study has shown that patients with colon cancer and a higher Immunoscore benefit the most from chemo in terms of recurrence risk.

An international study has shown...

10/06/2020

Oncology

News

Experts Convene to Debate and Discuss Updates in GI Cancer Care Research

08/10/2020

At the virtual 2020 Great Debates and Updates in GI Malignancies, experts in the oncology space will discuss and debate advancements in therapies for GI cancers.

At the virtual 2020 Great...

08/10/2020

Oncology

News

Carboplatin Plus Paclitaxel Superior to Cisplatin Plus FU in Advanced Anal Cancer

08/04/2020

Carboplatin plus paclitaxel should be considered as a new standard of care for advanced anal cancer, results from an international phase 2 trial suggest.

Carboplatin plus paclitaxel...

08/04/2020

Oncology

News

Researchers Propose Safe Alternative to Standard Coloanal Anastomosis After Resection for Low Rectal Cancer

07/30/2020

The 2-stage pull-through hand-sewn coloanal anastomosis is safe for use in patients with low rectal cancer who have undergone resection.

The 2-stage pull-through...

07/30/2020

Oncology

News

FDA Approves Pembrolizumab IV Injection as First-Line Immunotherapy for MSI-H/dMMR Metastatic CRC

06/29/2020

The FDA has approved pembrolizumab as an intravenous injection for the first-line treatment of patients with unresectable or metastatic MSI-H or dMMR CRC.

The FDA has approved...

06/29/2020

Oncology

News

Novel Plasma MDMs Accurately Detect Distant Recurrent CRC

06/17/2020

Study findings suggest that MDMs in plasma are a promising method for accurately detecting distant recurrent CRC.

Study findings suggest that MDMs...

06/17/2020

Oncology

News

Substantial Differences in Proportion of Cancer Drugs for Metastatic Disease, Adjuvant Use

05/01/2020

For patients with NSCLC, breast cancer, and colon cancer, there are considerable differences in the number of drugs available for use in the metastatic and adjuvant settings.

For patients with NSCLC, breast...

05/01/2020

Oncology

News

FDA Approves Encorafenib–Cetuximab Combo for BRAF V600E-Mutated mCRC

04/09/2020

The FDA has approved encorafenib plus cetuximab for the treatment of patients with pretreated metastatic CRC and a BRAF V600E mutation.

The FDA has approved encorafenib...

04/09/2020

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology